Lupus & antiphospholipid syndrome
Anti-SARS-CoV-2 mRNA vaccination among patients living with systemic lupus erythematosus (SLE) in Sweden: Coverage and clinical effectiveness
Main finding · COVID-19 hospitalizationResult — go to the resultHazard ratio 3.47 95% CI 1.63–7.39Authors' conclusion
Anti-SARS-CoV2 vaccination coverage was similar between SLE patients and the general population in Sweden. Even though the incidence of post-vaccination COVID-19 hospitalization was very low, vaccine effectiveness was diminished in SLE patients compared to the general population and lowest in those treated with immunosuppressants.
Study context
- Population
- SLE patients and matched comparators in Sweden; vaccine effectiveness among those with two mRNA doses before 2022 and no prior COVID-19 diagnosis
- Exposure
- SLE vs matched comparators
- SLEn = 5,585
- Comparatorsn = 37,102reference
- Outcome
- Hospitalization with COVID-19 as main diagnosis after second vaccine dose
- Follow-up
- Year after second dose
Methodological detailsnationwide register-based, matched comparators, multivariable-adjusted marginal Cox models
- Nationwide register-based
- Matched comparators
- Multivariable-adjusted marginal Cox models
Main finding
COVID-19 hospitalization
Hazard ratio
3.47
95% CI 1.63–7.39
Events by group
SLE
11
events
Comparators
20
events
SLEvs Comparators
HR 3.47 (95% CI 1.63–7.39)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| COVID-19 hospitalization by immunosuppressive treatment (subgroup) · year after second doseImmunosuppressive-treated SLEvs Comparators | 7.03 (3.00–16.46) | |
| COVID-19 hospitalization by immunosuppressive treatment (subgroup) · year after second doseImmunosuppressive-untreated SLEvs Comparators | 1.50 (0.34–6.60) | |
| 0.050.21520Hazard ratio (log scale) |
| Outcome | SLE | Comparators |
|---|---|---|
| No vaccine doses by December 2021 | 9% | 9% |
No vaccine doses by December 2021
- Vaccination uptake was similar between SLE patients and comparators
Original publication
Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness. Lupus. Published 12 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →